S2N.Bio commences technology transfer of Alzheimer’s cell therapy to Cell Therapies’ Melbourne GMP facility

Cell Therapies Pty Ltd and S2N.Bio (“S2N”) have commenced technology transfer of S2N’s cell therapy candidate for Alzheimer’s disease. The transfer will enable GMP manufacture of clinical trial material for S2N’s first-in-human study in Australia.

Read Original Copy